Polen Thomas E Jr reported disposition to issuer involving 17,246 shares of BECTON DICKINSON CO at $210.00 for −$3.62M on Nov 5, 2026

Disposition to issuer
Form 4 code D. Disposition of issuer equity securities to the issuer under Rule 16b-3(e).
Chairman, CEO and President
Chairman, CEO and President
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$3,621,660Shares × reported price
Shares traded
17,246Common Stock
Price per share
$210.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
113,156Direct
Trade date
Nov 5, 2026Disposition to issuer
Filed
Nov 9, 2026, 5:44 PM ET4-day reporting delay
Accession
0001628280-26-072360Code D · Transaction 396351
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Sell2,993$210.00−$628,530Trade 396352
Nov 5, 2026Option exercise20,239$0.00$0Trade 396353
Nov 5, 2026Option exercise20,239$178.94$3,621,566.66Trade 396350
4 transaction rows in this filing. Joint filers share the same rows.

BDX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BDX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −7.9%1d ago −2.8%
Returns since7d30d90d180d1y

Footnotes in full

F1: Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2: The stock appreciation rights vest in four annual installments beginning November 26, 2019.